SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 40.26 |
| Enterprise Value ($M) | 45.07 |
| Book Value ($M) | -23.22 |
| Book Value / Share | -1.37 |
| Price / Book | -1.73 |
| NCAV ($M) | -23.57 |
| NCAV / Share | -1.39 |
| Price / NCAV | -1.71 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -6.63 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.15 |
| Current Ratio | 0.15 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 3.30 |
| Assets | 3.65 |
| Liabilities | 26.87 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -19.70 |
| Net Income | -25.13 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -10.64 |
| Cash from Investing | 0.00 |
| Cash from Financing | 7.49 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Anson Funds Management LP | 7.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 185,482 | 552,286 | 33.58 | |
| 74,988 | 198,616 | 37.76 | |
| 259,722 | 704,547 | 36.86 | |
| 9,379 | 29,709 | 31.57 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NKTR – Nektar Therapeutics | NLSP – NLS Pharmaceutics AG |
| NRSN – NeuroSense Therapeutics Ltd. | NVCT – Nuvectis Pharma, Inc. |
| OCGN – Ocugen, Inc. |
Financial data and stock pages provided by
Fintel.io